Capital Markets Day: Commercial Execution and Innovation in Obesity Care
15
Commercial execution and innovation
Obesity care
In IO, only a fraction of people with obesity visit the doctor, let
alone are treated with a pharmacotherapy
SaxendaⓇ sales per region since 2019
Of the >550 million people with obesity
in IO, few are treated¹
3,117
+22%
2,083
2,118
1,809
~240 million
~250 million
981
1,124
1,247
1,093
984
9
2019
10
-61
2020
2021
EMEA
Rest of World
Region China
~75 million
~4 million people on AOM in IO
~700k people used SaxendaⓇ in 2021
Note: Obesity is defined as BMI > 30.
1 World Health Organization. 550 million people is data from 2016. Regional numbers are from 2021, but have been adjusted proportionally to give an estimate of 2016 numbers.
EMEA: Europe, Middle East and Africa; Region China: Mainland China, Hong Kong and Taiwan; AOM: Anti-obesity medications: IO: International Operations
opportunities
Local
Global
Future
Initiatives driving patient reach
HCP Locator
TRUTH ABOUT WEIGHT™
zur Rose
LloydsPharmacy
Geographic expansion e.g.
Japan and Region China
ONCE -WEEKLY
wegovy
semaglutide injection 2.4 mg
CMD22
CAPITAL MARKETS DAY
Novo NordiskⓇView entire presentation